高危出血风险学术研究联盟（The Academic Research Consortium for High Bleeding Risk，ARC-HBR）是由研究团体、监管机构和医生科学家组成的学术组织，专注于PCI相关出血的防控研究。 ARC-HRB专家共识将高危出血风险（High Bleeding Risk，HBR）定义为1年出血学术研究联合会（Bleeding Academic Research Consortium，BARC）定义的3级或5级出血风险≥4%，或1年颅内出血（intracerebral hemorrhage，ICH）风险≥1%（表2）。

2019年5月22日 · The proposed ARC-HBR consensus document represents the first pragmatic approach to a consistent definition of high bleeding risk in clinical trials evaluating the safety and effectiveness of devices and drug regimens for patients …

The American College of Cardiology/American Heart Association guidelines recommend that patients with HBR (Class IIb) discontinue P2Y 12 inhibitors after PCI at 3 months for stable ischemic heart disease and at 6 months for acute coronary syndrome (ACS). 1 However, how best to determine the HBR is still ill-defined, and early DAPT discontinuatio...

2019年6月7日 · The current publication by the BARC group identifies the ARC-HBR to more consistently identify the patient at HBR. The 20 clinical variables described have been associated with higher bleeding risk and are defined as major and …

Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores.

2019年9月11日 · ARC-HBR指出：当前临床缺乏对PCI患者高出血风险（HBR）患者标准化定义，对于试验设计、数据解读和临床决策也带来了困扰，制定统一的标准，方便临床医生设计研究、早期识别和管理、优化治疗至关重要。

As a member of the Academic Research Consortium, CERC developed a specific mobile application to identify High Bleeding Risk patients : The ARC-HBR evaluator is modelled on a consensus definition of High Bleeding Risk (HBR) for patients who are candidates for treatment with a coronary stent.

In patients with AF and ACS or undergoing PCI receiving both OAC and APT, the ARC-HBR score was a significant predictor of 1-year bleeding and ischemic endpoints. The ARC-HBR score performed better than the HAS-BLED score and the PRECISE-DAPT score in BARC type 3 or 5 bleeding prediction.

ARC-HBR 的次要标 准定义为符合下列条件：出血风险增加，1 年 BARC 3 型或 5 型出血风险 <4%。 共识以 BARC 3 型或 5 型出血发生率 4% 作为 HBR 的分界值，其原因是基于现有的大多数 PCI 术 后 DAPT 研究，在排除了 HBR 的患者后，其 1 年 主要出血率 <3%。

2020年8月28日 · Aims: The Academic Research Consortium for High Bleeding Risk (ARC-HBR) defined consensus-based criteria for patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI). We aimed to validate the ARC-HBR criteria for the bleeding outcomes using a large cohort of patients undergoing PCI.